Content writer – Clinical
Yogita Dhas is a Clinical Content Writer at Rhenix. She is responsible for writing scientific content and clinical white papers on healthcare-related topics, focusing mainly on oncology and immunology.
Yogita has a doctoral degree in life sciences from Symbiosis International (Deemed University), Pune, and her research work focused on diabetes and vitamin D.
At Rhenix, she has attained experience in scientific writing.
Stories
Summary "A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease"
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD) and affects around five million people worldwide. People with PD typically exhibit symptoms when 50%...
Summary "Grading of IDH‑mutant astrocytoma using diffusion, susceptibility, and perfusion‑weighted imaging"
The accurate grading of IDH-mutant astrocytoma is essential to develop therapeutic strategies and evaluating the prognosis of patients. A preoperative classification of these entities could be beneficial for the treatments...
Summary "Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas"
Meningiomas are the most prevalent primary central nervous system tumor, with a prevalence of 170,000 cases in the United States. Maximal safe resection is the cornerstone of meningioma treatment, and adjuvant radiation...
.jpg)
Videos
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease | CellTalk
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD) and affects around five million people worldwide. People with PD typically exhibit symptoms when 50%...
Grading of IDH‑mutant astrocytoma using diffusion, susceptibility, and perfusion‑weighted imaging | CellTalk
The accurate grading of IDH-mutant astrocytoma is essential to develop therapeutic strategies and evaluating the prognosis of patients. A preoperative classification of these entities could be beneficial for the treatments of patients, particularly...
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas | CellTalk
Meningiomas are the most prevalent primary central nervous system tumor, with a prevalence of 170,000 cases in the United States. Maximal safe resection is the cornerstone of meningioma treatment, and adjuvant radiation may be...
